{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for dexamethasone root_names_stdName in Standardized Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
M016
(2024)
Source URL:
First approved in 2024
Source:
M016
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
Unknown by Shizuoka College of Pharmacy
Source URL:
First approved in 2024
Source:
M017
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Ligustrazine (tetramethylpyrazine) is a bioactive ingredient extracted from the widely-used Chinese herb, Chuanxiong. It inhibits of platelet aggregation, enhances of vessel dilation, increases cerebral blood flow and possesses neuroprotective properties. The injection solution of ligustrazine has been used especially in China to treat ischemic stroke, coronary heart disease, diabetic nephropathy, and knee osteoarthritis. Ligustrazine was also evaluated in clinical as a remedy for pressure sores, as a salvage agent for patients with non-Hodgkin's lymphoma, as a treatment for bronchial asthma and vertebrobasilar insufficiency.
Status:
Possibly Marketed Outside US
Source:
BLA125734
(2023)
Source URL:
First approved in 2023
Source:
BLA125734
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Uridine 5'-triphosphate (UTP, INS316) is a naturally occurring agonist for P2Y(2) receptors on the apical surface of ciliated respiratory epithelium. INS316, being developed by Inspire Pharmaceuticals, is a short-acting, aerosolized uridine 5-triphosphate (UTP) solution used as a diagnostic aid for lung cancer. INS316 appears to improve sputum expectoration mediated through the P2Y2 receptor, a nucleotide receptor expressed in human airway epithelial cells and some other tissues. UTP binding to the P2Y2 receptor triggers signal transduction that leads to chloride ion secretion, thereby resulting in mucociliary clearance of airway. UTP stimulates salt and water transport and cilia beat frequency in human airway epithelium in vitro. Single, inhaled doses of UTP stimulate mucociliary clearance in conscious, intubated sheep and in patients with mild chronic bronchitis (smokers and former smokers), suggesting that UTP may be useful for obtaining deep-lung sputum specimens suitable for diagnostic purposes. A single dose of INS316 safely improves the ability of patients with mild chronic bronchitis to expectorate a deep-lung sputum specimen suitable for cytologic evaluation.
Status:
Possibly Marketed Outside US
Source:
Chloroquine Diphosphate by KDG Impresa LLC, Aqion
(2022)
Source URL:
First approved in 2022
Source:
Chloroquine Diphosphate by KDG Impresa LLC, Aqion
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
M017
(2024)
Source URL:
First approved in 2021
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
1-Palmitoyl-2-oleoyl-sn-glycero-3-phospho-rac-(1-glycerol) ammonium salt (POPG-NH4) ia a phospholipid. Can be used as an emulsifier in pharmaceutical compositions. Used for lipid modification of superhydrophobic surfaces. POPG-NH4 transforms the surface into a highly hydrophilic surface only at the positions where the solution is applied.
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2020)
Source URL:
First approved in 2020
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M019
(2020)
Source URL:
First approved in 2020
Source:
M019
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
There has been little to no interest in the biological and/or pharmacological application of lauryl phosphate.
Status:
Possibly Marketed Outside US
Source:
M019
(2020)
Source URL:
First approved in 2020
Source:
M019
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
There has been little to no interest in the biological and/or pharmacological application of lauryl phosphate.